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Diabetic complications, comorbidities, and cost of treatment affect the quality of life (QoL) of an 
individual. The QoL assessment is considered an important measure of outcome in chronic disease 
management. The objective of our study was to assess the quality of life in Type II diabetes mellitus 
patients with and without complications using the modified diabetes quality of life (MDQoL)-17. A 
prospective descriptive study was conducted over 6 months, after taking ethical committee approval. 
As per the inclusion criteria from medicine wards of tertiary care hospital, 250 patients were selected. 
Demographic characteristics were documented in the data collection form and the patients were 
administered with the MDQoL questionnaire in different languages. The data was analyzed using IBM 
SPSS version 20. Majority of the patients were male (64.4%). The average age of the study population was 
60.34±12.04 years. Most of the patients had a diabetes history of more than 10 years and HbA1c > 8%. 
The average QoL score was 65.47±15.07. Majority of the diabetic patients had the QoL score between 70 
and 50. Patients without complication had a better QoL. As the number of complications increased, there 
was a decrease in the QoL. The presence of comorbidity also decreased the QoL. There was a statistically 
significant correlation with various parameters such as age, duration of diabetes history, HbA1c, number 
of complications and type of complication verses QoL of diabetic patients (p<0.05). The overall QoL in 
diabetic patients is reduced. Thus, proper management and strict glycemic control is necessary to prevent 
progression and occurrence of complications to maintain a better QoL in diabetes patients.
Keywords: Quality of Life. Diabetes complications/prevention and control. Diabetes Mellitus. Surveys 
and Questionnaires/utilization.
INTRODUCTION
The quality of life (QoL) in general is decreased in 
diabetic patients regardless of the gender. The patients with 
complications of diabetes mellitus suffer from a variety of 
lifestyle problems. In the end, it affects the renal system by 
causing nephropathy, vision loss, heart problems, erectile 
dysfunction, and peripheral neuropathies affecting the 
QoL. In one cohort study, it was found that there was an 
improvement in mental QoL more than physical QoL when 
there was a tight glycemic control (Lau, Qureshi, Scott, 
2004). Rubin et al. (1999) stated in their study that the 
patients suffering from diabetes had a poor quality of life 
than the patients without any disease, but had somewhat 
higher QoL than the patients with the majority of other 
chronic illness. The mere presence of diabetes can reduce 
the quantity and quality of any relationship, family life, 
and hindrance in traveling and increase in economic 
burden (Polonsky, 2000). Education on self-control had 
more impact on controlling the condition and improving 
the quality of life as shown by one meta-analysis (Gerstein 
et al., 2011).
According to the result of International Diabetes 
Federation (2015), there are 415 million people worldwide 
suffering from diabetes and 78.3 million are from South 
East Asia. India is the second largest worldwide with 
diabetes population, after China (International Diabetes 
Federation, 2015). Diabetes has become increasingly 
prevalent and demands better care and control. The quality 
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of life assessment is considered an important measure of 
outcome in long-term illness and management. General 
quality of life assessment tools used for diseases are Short 
Form 36 (SF-36 Health Survey), a Rand-36 measure of 
health-related quality of life, and The Euro QoL (EQ) 
(Acharya et al., 2014). Tools for measuring the quality 
of life are Problem areas in diabetes (PAID), Diabetes 
Treatment Satisfaction Questionnaire (DTSQ), Appraisal 
Diabetes Scale (ADS) (Acharya et al., 2014), and Medical 
Outcomes Study (MOS) is also used for diabetic patients. 
The MOS instrument includes physical, social, role 
functioning scales to capture behavioral dysfunction due 
to health problems. Measuring different areas of quality 
of life requires various domains, specifically for example, 
physical, psychological, social, and functioning aspects 
(Stewart et al., 1989). From an analytical point of view, 
the quality of life assessment has been used to give a 
reference norm, better prognosis, signal change in the 
patient’s perspective.
The studies on QoL help in the evaluation of the 
psychological functioning of a patient, identification of 
specific shortcomings, and the needs of patients at different 
stages of the disease. They also help in comparing the 
impact of different treatment regimens on a patient’s well-
being and satisfaction (Snoek, 2000). These results from 
the study of QoL can help a clinicians’ ability to predict, 
treatment response, and survival time in certain contexts 
(Acharya et al., 2014). Such comparative studies have 
equipped the clinicians with important information to 
support clinical decision-making, taking both biomedical 
and psychosocial aspects into consideration (Snoek, 2000). 
Most health care providers focus on medically 
related outcomes only when assessing the efficacy of their 
intervention, thus for a better outcome it is important to 
extend the assessment of the effect on physical, emotional, 
social and economic wellbeing that is, the quality of life.
Diabetes is a chronic illness therefore there is a need 
for assessing the QoL of patients at regular intervals. The 
complications of diabetes affect the organ system and are 
responsible for the majority of morbidity and mortality 
associated with the disease (Power, 2008). 
The QoL is very important because it is a powerful 
tool to predict an individual’s capacity to manage 
the disease and maintain long-term health and well-
being (Rubin, 2000). Routine assessment of QoL as 
a part of clinical practice has the potential to improve 
communication between the patient and the health care 
provider, identify frequently overlooked problems, assess 
the problems, and evaluate the effect of therapeutic efforts 
at the individual patient’s level (Acharya et al., 2014).
In our study, we have used MDQoL-17 questionnaire 
developed by Acharya et al. (2014). It contains 17 diabetic 
specific questions and 8 concepts for physical, social 
functioning, role limitations due to personal and emotional 
problems, psychological impact, energy/fatigue, bodily 
pain, and general health perceptions. This was used to 
assess the QoL in Type II diabetes mellitus patients with 
and without complications and get a better understanding 
of the patients’ perspective regarding the disease and 
impact of disease on their QoL.
METHODOLOGY
This prospective descriptive study was conducted 
in the General Medicine units of Tertiary care hospital in 
South India, after obtaining Ethical Committee approval 
from the Institutional Ethics committee. The study 
was done for a total duration of six months. During the 
study period, 250 patients were recruited with Type II 
diabetes based on the following inclusion and exclusion 
criteria. The selected patients were administered with the 
MDQoL-17 questionnaire and recorded the demographics 
information in the data collection form after obtaining 
their consent. 
Acharya et al. (2014) developed and validated the 
MDQoL-17 questionnaire in the year 2010 in the local 
South Indian languages - Kannada and English. It consists 
of 17 questions that comprise seven domains, which include 
physical functioning, role limitations due to physical health 
problems, role limitations due to personal or emotional 
problems, emotional well-being, social functioning, energy/
fatigue, and general health perceptions. All the contents are 
scored so that a high score depicts a more favorable health 
state. The possible scores are 0-100, 0 being the minimum 
and 100 being the maximum score Scores represent the 
percentage of total possible score achieved. The various 
domains, number of items in each domain, and item 
numbers that come in that particular domain and their scores 
are shown in Tables I and II.
Data were analyzed using IBM SPSS statistics 20 
software for various demographic parameters such as 
gender, age group, duration of diabetic history, the number 
of diabetic drugs prescribed, the prescription pattern of 
diabetic drugs, laboratory tests on admission and the time 
taken for interview and the QoL.
The QoL score of MDQoL-17 was expressed as a 
percentage of the total QoL Score for ease of comparison 
and analysis. Those patients with a QoL score of more than 
70 had a better QoL, those with a QoL score of 50-70 had a 
moderate QoL, and those with less than 50 had a poor QoL.
Descriptive statistics was used to express various 
demographic parameters. For the comparison of the QoL 
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Score and covariates, demographics, diabetic related 
complaints, comorbidities, diabetes with and without 
complications etc. unpaired ‘T’ test (also known as 
independent ‘T’ test) was applied for comparing the mean 
of two groups and for comparing the means of three of 
more groups the one way ANOVA test was applied. P value 
<0.05, was considered significant.
RESULTS
As per the study criteria, the 250 diabetic patients 
admitted were included and the majority of them were 
male members as shown in Table III.
Among the 250 patients, 16 (6.4%) patients were in 
the age group of less than 40 years, 142(56.8%) were in 
the age group of 40-65 years, and 89(35.6%) were falling 
under the age group of more than 65years. The mean age 
of patients was found to be 60.34±12.04 years. 
We observed that out of 190 patients, 27 (14.2%) had 
the history of diabetes less than 1year, 30(15.8%) had a 
history of 1-5 years, 57(30%) of 6-10 years, and 76 (40%) 
of more than 10 years.
Patients 155(62%) were hospitalized for less than 10 
days, 67 (26.8%) for 10-20 days, and 22(8.8%) for more 
than 20 days. The mean duration of hospitalization in the 
diabetic patients was found 11.07±.8.55 days.
Out of 250 patients, 116 (46.4%) had health 
insurance and 134 (53.6%) did not have any health 
insurance. Patients were prescribed with 1 to 4 medications 
for diabetes treatment; the majority of the patients were on 
monotherapy (Table III). 
There were 94 (37.6%) patients being treated with 
insulin monotherapy, 80 (32%) were on oral hypoglycemic 
agents, and 62 (24.8%) were taking a combination of 
insulin and oral hypoglycemic agents. 
Among the diabetic patients, many had other 
comorbidities present, such as hypertension (HTN), 
kidney disease, liver disease, and other diseases as shown 
in Table III. Various tests were performed to determine the 
glycemic control, fasting blood sugar (FBS), glycosylated 
hemoglobin (HbA1c), and the body mass index (BMI) at 
the time of admission. Details are shown in Table III. 
On analysis of MDQoL-17 questionnaires, the 
average QoL score was 65.47±15.07. The number of 
patients under a different range of QoL score is represented 
in Table IV.
The correlation between the QoL score and the 
number of diabetic complications is described in Table V. 
Eighty-seven patients had various types of complications; 
retinopathy, nephropathy, neuropathy, diabetic foot, 
Ischemic Heart Disease (IHD) and ketoacidosis. The 
patients with diabetic neuropathy had the least QoL score 
(53.99±16.39) and the patient with diabetic retinopathy 
had a better QoL score (65.20±18.16) compared to other 
complications (Table V). 
The QoL in comparison to the demographic 
characteristics of the patient showed that there was no 
significant difference in the QoL scores between male and 
female. As the age increased the QoL decreased, patients 
less than 40 years had a better QoL while those more than 
65 years had comparatively a poor QoL.
The patients without comorbid condition had a 
better QoL than the patients with comorbidity. The QoL 
in different types of cormorbidity is described in Table 
V. QoL in patients with a diabetes history of less than 
1 year was better and as the duration increased the QoL 
decreased, those with more than 10-year diabetic history 
had a lower QoL. QoL score for a patient hospitalized 
TABLE I - MDQoL-17 Domains and item numbers
Domains Number of Items
Item 
Numbers
Physical functioning 3 4,5,6
Role limitations due to physical 
health
1 7
Role limitations due to emotional 2 11,12
Energy Fatigue 1 17
Emotional well being 3 8,9,10
Social functioning 4 13,14,15,16
General Health 3 1,2,3
TABLE II - Response category and scores of MDQoL-17
Item Number Response category and Scores
1,2,7,13 1→100,2→75,3→50,4→25,5→0
3 1→0,2→25,3→50,4→75,5→100
4,5,6 1→0,2→50,3→100
8,9,10,11,12,14,15,16 1→0,2→20,3→40,4→60,5→80,6→100
17 1→100,2→80,3→60,4→40,5→20,6→0
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less than 10days was better than for patient hospitalized 
for more than 20day, as the duration of hospitalization 
increased the QoL decreased.
Patients prescribed with a combination of insulin and 
OHA had a better QoL than patients on monotherapy of 
only insulin or OHA. Patients on OHA monotherapy had 
a slightly Better QoL than those on insulin monotherapy. 
Diabetic patients without Complications had a better 
QoL in comparison to those with complications, and the 
minimum QoL score was in patients having diabetes with 
three complications. 
The QoL for patients with health insurance was 
slightly better compared to those without health insurance. 
The patients with a BMI of less than or equal to 18.4kg/m2 
had higher QoL score than the others and those with BMI 
of 18.5-22.9 had the lowest QoL score. The patients with 
HbA1c between 4% - 7% had a lower QoL in contrast to 
those with an HbA1c of more than 8% who had a better 
QoL score. The details of correlation of QoL score with 
various demographics characteristics of diabetic patients 
are represented in Table V.
The QoL of diabetic patients was assessed with 
respect to diabetes-related complaints, it was found that 
fatigue, sleep disturbances, polyuria, problems in work 
life, decreased energy levels, hypoglycemic symptoms, 
tingling sensation/numbness, problems in social life, 
difficulty in walking, swelling in limbs, pain in limbs, and 
delayed wound healing statistically significantly effect on 
QoL, reduces the QoL scores. However, weight change 
and blurred vision did not have a statistically significant 
difference in the QoL score. The detailed summary of the 
result is given in Table VI.
DISCUSSION
The present study is aimed at assessing the QoL 
in Diabetic patients in a tertiary care hospital where 250 
patients were admitted. We found that the patients with 
diabetes had generally a negative impact on the QoL 
(65.47±15.07). This is supported by the studies done 
by Gautam et al. (2009) and Anumol et al. (2014) both 
concluded that diabetes had an adverse effect on the QOL 
of the patient.
The majority of the study subjects were males 161 
(64.4%) and this was similar to the observation from 
the study carried out by Eljedi et al. (2006) in which the 
majority of the patients were males.
The mean age of diabetic patients was found to be 
60.34±12.04 years and Ali et al. (2013) made a similar 
observation in their study and reported the mean age 
59.65±12.3 years. Majority of the patients (n=142) were 
TABLE III - Demographics of Diabetes patient
S.No Category Number of patients (%)
1 Gender  
N=250
Male 161(64%)
Female 89 (36%)
2 Fating Blood 
Sugar (mg/dl) 
N= 142
Less than 110 36 (25.4%)
110-126 8 (5.6%)
More than 126 98 (69%)
3 HbA1c (%) 
N=168
4-7 38 (22.6%)
7-8 28 (14.3%)
More than 8 106 (63.1%)
4 BMI (Kg/m2)
N=130
≤18.4 9 (6.9%)
18.5-22.9 32 (24.6%)
23-24.9 18 (13.8%)
≥25 71 (54.6%)
5 Comorbidity HTN 124 (49.6%)
Kidney Disease 46 (18.4%)
Liver Disease 12 (4.8%)
6 DM with 
and without 
Complication
DM Without 
Complication
163 (65.2%)
DM+1 
complication
65 (26%)
DM+2 
complication
13 (5.2%)
DM+3 
complication
7 (2.8%)
DM+4 
complication
2 (0.8%)
7 Types of Diabetic 
Complication
Retinopathy 22 (25.3%)
Nephropathy 24 (27.6%)
Neuropathy 14 (16.1%)
Diabetic foot 17 (19.5%)
IHD 39 (44.8%)
Ketoacidosis 5 (5.7%)
8 Number of 
diabetic drugs 
prescribed 
N=250
One 134 (53.6%)
Two 61 (24.4%)
Three 38 (15.2%)
Four 3 (1.2%)
TABLE IV - Assessment of QoL of diabetic patients 
QoL Score No. of patients (%)  N=250
Less than 50 40(16%)
50-70 106(42.4%)
More than 70 103(41.2%)
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TABLE V - Correlation of QoL with various demographics characteristics of diabetic patients
S.no Covariate factors QOL scores (Mean ± S.D) p values
1 Gender
Male 65.71±16.08 0.713
Female 65.02±13.15
2 Age (years)
Less than 40 71.47±14.16 0.024
40-65 66.83±14.86
More than 65 62.38±15.16
3 Comorbidity
Present 64.37±14.75 0.179
Absent 67.09±15.55
4 Type of Comorbidity
HTN 64.39±14.56 >0.05
Kidney disease 62.12±15.03
Liver disease 63.24±16.81
5 Duration of Illness (years)
<1 75.93±10.93 0.004
1-5 68.15±16.34
6-10 65.56±15.33
>10 63.88±14.18
6 Length of stay in hospital (days)
<10 66.49±15.53 0.370
10-20 64.40±14.79
>20 62.27±13.73
7 Patients diabetic Medication
Insulin 63.95±15.97 0.279
OHA 65.92±14.92
Insulin+ OHA 67.89±14.08
8 Health insurance status
Present 66.69±15.28 0.238
Absent 64.42±14.88
9 Diabetes with and without Complication
DM without complications 66.80±14.51 >0.05
DM+1 complications 64.87±14.66 >0.05
DM+2 complications 60.59±20.16 >0.05
DM+3 complications 50.04±14.29 0.031
DM+4 complications 62.94±16.63 >0.05
10 Type of Diabetic Copmlication
Retinopathy 65.20±18.16 0.931
Nephropathy 58.24±16.94 0.013
Neuropathy 53.99±16.39 0.003
Diabetic foot 63.34±15.94 0.547
IHD 63.88±15.10 0.476
Ketoacidosis 58.65±10.24 0.308
11 BMI (kg/M2)
≤18.4 70.46±11.76 0.572
18.5-22.9 65.73±14.52
23-24.9 66.08±12.28
≥25 69.29±14.68
12 HbA1c (%)
4-7 59.05±18.06 0.025
7-8 67.59±13.81
>8 66.49±13.89
P< 0.05, was considered statistical significant
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in the age group between 40-65 years as observed in a 
study of global prevalence in diabetes by Wild at al. (2004) 
which stated that in the developing countries, majority 
of the people with diabetes are in the age range of 45-65 
years. King et al. (1998) made a similar observation in 
their study. We also observe as the age increases there is 
a significant decrease in the QoL score (p= 0.024). Ali 
et al. (2013) and Glasgow et al. (1997) made a similar 
observation in a study, where an increase in age decreased 
the QoL in diabetes patients.
In our study, majority of diabetic patients had a 
history more than 10 years, their QoL score was poor 
compared to those with a history of less than 10 years, 
and Shirish, Priya, and Ahsan (2011) made a similar 
observation in their study. We observed in the study that 
as the duration of history increased there was a significant 
decrease in the QoL (p=0.004).
The QoL score for the patients on combination 
therapy with insulin and OHA was better than the patients 
on monotherapy do with only insulin or OHA. These may 
be attributed to the fact that using combination therapy 
of insulin and OHA gives a better glycemic control. The 
studies by Hermanns et al. (2015) and Yki-Järvinen (2001) 
both reported that the combination of insulin with OHA 
TABLE VI - Assessment of QoL based on the diabetes related complaints
S.no Diabetes related complains QOL scores (Mean ± S.D) p values
1 Fatigue Present (n=189) 62.47±14.70 <0.0001
Absent (n=60) 74.90±12.14
2 Sleep disturbances Present( n=104) 61.52±13.90 <0.0001
Absent(n=146) 68.30±15.29
3 Polyurea Present (n=84) 61.72±17.01 0.005
Absent (n=165) 67.37±13.65
4 Weight change No change(n=91) 66.47±14.07 0.126
 Loss (n=119) 63.61±16.31
Gain(n=39) 68.82±12.77
5 Problems in work life Yes(n=134) 60.79±14.51 <0.0001
No(115) 70.92±13.89
6 Decreased Energy Levels Yes (n=180) 61.63±14.40 <0.0001
No (n=69) 75.48±11.91
7 Hypoglycemic symptoms Present (n=109) 60.36±15.25 <0.0001
Absent (n=140) 69.45±13.72
8 Tingling sensation/Numbness Present (n=132) 60.64±14.88 <0.0001
Absent (n=117) 70.92±13.38
9 Blurred vision Present (n=103) 63.33±14.87 0.059
Absent (n=146) 66.98±15.08
10 Problems in social life Present (n=53) 56.41±17.47 <0.0001
Absent (n=196) 67.92±13.39
11 Difficulty in walking Present (n=169) 60.81±14.07 <0.0001
Absent (n=80) 75.30±12.71
12 Swelling of limbs Present (n=90) 61.44±14.77 0.001
Absent (n=159) 67.75±14.80
13 Pain in limbs Present (n=140) 60.91±14.87 <0.0001
Absent (n=109) 71.32±13.25
14 Delayed wound healing Yes (n=73) 59.66±16.25 <0.0001
No (n=176 ) 67.88±13.90
P< 0.05, was considered statistical significant
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had a better glycemic control, less adverse effect and better 
outcome in type 2 diabetic patients.
The subjects with Health insurance had a better 
Quality of life than those without insurance, these can be 
attributed to regular checkup, and the insurance company 
covers medication adherence as the cost. 
The patients with a BMI of <18.4 Kg/m2 had a 
better QoL than the patients with a BMI >25 kg/m2, but 
there is no statistically significant difference in the QoL 
scores, previously the studies independently looking at 
the association between obesity and Qol have clearly 
indicated that the obesity impairs the QoL (Kolotkin, 
Meter, Williams, 2001). A study in from Stanford also 
showed that among diabetics, the presence of obesity 
significantly impaired QoL (Hlatky, et al., 2010).
Patients with HbA1c 7-8% had a better QoL life 
(67.59±13.81) compared to the patients with HbA1c levels 
between 4-7% and more than 8%. A study by Stanetić et 
al. (2012) reported the similar result that the poor QoL 
was observed in the patients with poor glycemic control 
and levels of HbA1c >8.1%. It also stated that the better 
QoL was found in patients with HbA1c level between 7.1 
-8.0%. 
The QoL decreased in the presence of comorbidity, 
and Jiménez-Garcia et al. (2008) made the similar 
observation in their study that reported comorbidities as a 
predictor of poor QoL. There was no statically significant 
difference in the score as seen in a study by Shirish, Priya, 
Ahsan (2011) and Jiménez-Garcia et al. (2008). We also 
observed that the most predominant Comorbidity was 
hypertension [124(49.6%)] and followed by chronic renal 
failure [46(18.4%)] in diabetic patients. Similar results 
were seen in the studies by Gautam et al. (2009), Wexler et 
al. (2006) and Spasić et al. (2014) in diabetes patients the 
most frequent comorbidity was hypertension. In a study 
by Acharya et al. (2016), it was reported that more than 
50% of the total diabetes patients had hypertension and 
the similar observation is reported in our study.
The diabetic patients without complications had 
a better QoL compared to the patients with diabetic 
complications, and as the number of complications 
increased the QoL score decreased. The most commonly 
observed diabetic complication was IHD [39(44.8%)] and 
the other complications were retinopathy [22(25.3%)], 
nephropathy [24(27.6%)], neuropathy [14(16.1%)]. 
Similar observations were seen in a survey and chart 
review that was conducted to assess the health-related 
quality of life among 2285 Type II diabetes people in 
Canada. The study results showed that the most prevalent 
diabetic complications were coronary artery disease 
(16%), retinopathy (15%), cerebrovascular accidents 
(9%), neuropathy (9%), peripheral vascular disease (7%), 
and nephropathy (6%). The study concluded that the 
people with diabetes experience significant impairment 
in their health-related quality of life; the presence 
of diabetic complications significantly affects some 
health-related quality of life of Type II diabetes mellitus 
patients (Thommasen, Zhang, 2006). Our study showed 
a statistically significant decrease in QoL (53.99±16.39) 
in the patients with neuropathy (P=0.003). It was also 
observed that among the diabetic complications the 
patients with neuropathy had the least QoL score, which is 
similar to the study by Benbow et al. (1998) who reported 
that neuropathy impairs the QoL. The patients with 
nephropathy had a lower QoL (58.24±16.94) and there 
was a statistically significant difference in the QoL scores 
(P=0.013) compared to the patients without complications, 
and it is supported by a study by Lauro et al. (2005) who 
reported that the patients with diabetic nephropathy 
showed deterioration in the QoL.
Diabetic related complaints fatigue,  sleep 
disturbances, polyurea, problems in work life, decreased 
energy levels, hypoglycemic symptoms, tingling 
sensation/numbness, problems in social life, difficulty 
in walking, swelling in limbs, pain in limbs and delayed 
wound healing significantly reduce the QoL scores 
(P<0.001). Benbow et al. (1998) reported the similar 
observation where the patients complaining of fatigue and 
pain in limb had poor QoL. 
The limitations we encountered were failure 
to obtain an equal number of patients with different 
complications, without diabetic complications for better 
comparison of outcome, and the short duration of the 
study period.
CONCLUSION
In conclusion, the study was carried out to 
evaluate the QoL in Type II diabetic patients with and 
without complications. Among the 250 Diabetic patients 
enrolled, the majority of them were male, the mean age 
of diabetic patients was 60.34±12.04 years, and majority 
had a history of diabetes for more than 10 years. Most 
of the patients [106(42.4%)] had a moderate QoL score 
between 50 and 70.There are various factors such 
as age of the patient, duration of history of diabetes, 
and HbA1c significantly reduce the QoL of diabetic 
patients (p<0.05). The presence of complication and 
comorbidity had an adverse effect on the QoL of diabetic 
patients, as the number of complications increased the 
QoL decreased and hypertension was the predominant 
comorbid condition.
V. B. Prajapati, R. Blake, L. D. Acharya, S. Seshadri
Braz. J. Pharm. Sci. 2017;53(4):e17144Page 8 / 9
Overall patients with Type II diabetes have a 
negative impact on their quality of life with or without 
complications. It also shows that diabetes affects various 
domains such as physical functioning, emotional well-
being, social functioning, economical status, and general 
health in a patient’s life, thereby affecting the QoL. Hence, 
it is recommended for patients to have an adequate and 
strict glycemic control enabling them to maintain their 
quality of life, preventing disease progression and diabetic 
complications.
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